- IQVIA demonstrates a strong sequential growth pattern, in near recovery to pre-pandemic volumes.
- Management have reinstated the buyback program, with ~$1 billion in authorization, and look set on acquisition targeting across FY2021.
- We feel shares are worth ~$197 at this point, and believe a December 2021 price target of $239 is not unreasonable at the current run rate.
- Investors should pay close attention to the AZN/ALXN transaction to observe any inflection on IQVIA's chart performance.
- Here, we cover all of the moving parts in the investment debate for the benefit of investors in their own reasoning.
For further details see:
IQVIA Holdings: Upside Potential, Key Levers Overlooked By Sell-Side